Vendor Idiosyncrasies, Disjoined Research Efforts, and Ignorance Can Spoil Biomarker Studies, Pharma Official Says | GenomeWeb
PHILADELPHIA (GenomeWeb News) — As drug makers increasingly use biomarkers to help them understand disease and drug activity, a passel of seemingly simple human oversights threatens to muddy results, according to a senior pharma official.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.